Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Transdermal Drug Delivery Systems01:18

Transdermal Drug Delivery Systems

Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...
Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices01:28

Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices

Parenteral drug delivery systems play a crucial role in modern therapeutics by enabling the direct administration of drugs into the systemic circulation, bypassing the gastrointestinal tract. These systems are particularly valuable for poorly absorbed oral medications that are unstable in the digestive environment or require rapid onset or sustained therapeutic levels. Delivery is achieved through intravenous, intramuscular, or subcutaneous routes, each selected based on the drug's properties...
Modified-Release Drug Delivery Systems: Rate-Programmed I01:22

Modified-Release Drug Delivery Systems: Rate-Programmed I

Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
Modified-Release Drug Delivery Systems: Drug Release Characteristics01:22

Modified-Release Drug Delivery Systems: Drug Release Characteristics

Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.There are four major models of drug release patterns. The first model is the slow zero-order...
Modified-Release Drug Delivery Systems: Stimuli-Activated01:30

Modified-Release Drug Delivery Systems: Stimuli-Activated

Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also called...
Intrauterine Drug Delivery Systems01:21

Intrauterine Drug Delivery Systems

Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Special issue of nonclinical statistics in regulatory applications guest editors' notes.

Journal of biopharmaceutical statistics·2026
Same author

Comparison of <i>in-vitro</i> release rates for vaginal systems.

Journal of biopharmaceutical statistics·2026
Same author

Statistical approaches for shelf-life determination of a drug product.

Journal of biopharmaceutical statistics·2026
Same author

Parallelism of four-parameter logistic bioassay models: equivalence testing for parameter differences.

Journal of biopharmaceutical statistics·2026
Same author

A survey of parallelism testing methods for bioassays.

Journal of biopharmaceutical statistics·2026
Same author

A multivariate equivalence test based on Mahalanobis distance with a data-driven margin.

Journal of biopharmaceutical statistics·2026

Related Experiment Video

Updated: Jun 16, 2026

Development, Characterization, and Evaluation of CAGE-based Ionic Liquid Systems for Transdermal Delivery
09:44

Development, Characterization, and Evaluation of CAGE-based Ionic Liquid Systems for Transdermal Delivery

Published on: September 26, 2025

Release liner removal method for transdermal drug delivery systems (TDDS).

Anna M Wokovich1, Meiyu Shen, William H Doub

  • 1Food and Drug Administration, Center for Drug Evaluation and Research, St. Louis, Missouri, USA. anna.wokovich@fda.hhs.gov

Journal of Pharmaceutical Sciences
|February 6, 2010
PubMed
Summary

This study establishes standardized methods for testing the release liner adhesion of transdermal drug delivery systems (TDDS). These parameters ensure consistent quality assessment for TDDS patches.

More Related Videos

Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions
07:49

Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions

Published on: September 17, 2014

Dissolving Microneedle Array Patches Manufactured By Solvent Casting Technique and Essential Characterization of Microneedle-Based Biomedical Devices
08:26

Dissolving Microneedle Array Patches Manufactured By Solvent Casting Technique and Essential Characterization of Microneedle-Based Biomedical Devices

Published on: January 30, 2026

Related Experiment Videos

Last Updated: Jun 16, 2026

Development, Characterization, and Evaluation of CAGE-based Ionic Liquid Systems for Transdermal Delivery
09:44

Development, Characterization, and Evaluation of CAGE-based Ionic Liquid Systems for Transdermal Delivery

Published on: September 26, 2025

Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions
07:49

Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions

Published on: September 17, 2014

Dissolving Microneedle Array Patches Manufactured By Solvent Casting Technique and Essential Characterization of Microneedle-Based Biomedical Devices
08:26

Dissolving Microneedle Array Patches Manufactured By Solvent Casting Technique and Essential Characterization of Microneedle-Based Biomedical Devices

Published on: January 30, 2026

Area of Science:

  • Pharmaceutical Sciences
  • Materials Science
  • Biomedical Engineering

Background:

  • Transdermal drug delivery systems (TDDS) require robust quality control measures.
  • Release liner adhesion is a critical factor in TDDS performance and patient usability.
  • Standardized testing protocols are essential for reliable assessment of TDDS quality.

Purpose of the Study:

  • To establish precise sample preparation techniques for transdermal drug delivery systems (TDDS).
  • To define optimal instrument parameters for measuring release liner removal adhesion in TDDS.
  • To develop a reliable method for assessing the quality of TDDS based on liner adhesion.

Main Methods:

  • Evaluated ten TDDS across six drugs and 29 lots.
  • Developed specific preparation methods based on patch geometry and membrane presence.
  • Utilized a standardized peel adhesion test with a 90-degree angle, 3 min dwell time, and 300 mm/min peel speed.

Main Results:

  • Successfully adapted sample preparation for various TDDS configurations, including those with rate-controlling membranes.
  • Demonstrated the feasibility of the proposed release liner peel adhesion method for TDDS.
  • Established consistent parameters for measuring release liner removal force.

Conclusions:

  • The proposed method provides a reliable approach for assessing TDDS release liner adhesion.
  • Standardized testing enhances the quality control and consistency of transdermal drug delivery systems.
  • This research contributes to the development of high-quality and user-friendly TDDS.